Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab therapeutic drug monitoring dose-reduction pilot in rheumatoid arthritis
NL-OMON44574Phase 4Recruiting
- Sponsor
- Amsterdam Rheumatology and immunology Center | Reade
- Start
- Jun 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of tocilizumab in rheumatoid arthritis (RA), sponsored by Amsterdam Rheumatology and immunology Center | Reade. Primary endpoints: Feasibility of study logistics, Completion of 20-week follow-up and 2 more. Started Jun 2018; status: recruiting.
02
Drugs
tocilizumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NL-OMON44574.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44574.